Table 1.
Baseline Patient Characteristics
| Patient | Age (Years) | Gender | Indication | CAD | LVEF (%) | β‐Blocker | Antiarrhythmic | PVC/VT Morphology |
|---|---|---|---|---|---|---|---|---|
| 1 | 66 | M | PVC | Yes | 35–40 | Carvedilol | None | LBBB |
| 2 | 75 | M | PVC | No | 45–50 | Metoprolol | None | RBBB |
| 3 | 27 | M | PVC | No | 55–60 | None | None | LBBB |
| 4 | 71 | M | PVC | No | 60–65 | None | None | Polymorphic |
| 5 | 61 | F | PVC | No | 40–45 | Metoprolol | None | LBBB |
| 6 | 54 | F | PVC | No | 20–25 | Carvedilol | None | LBBB |
| 7 | 60 | M | Incessant VTa | Yes | 30 | Carvedilol | Dronedarone | RBBB |
| 8 | 66 | M | Incessant VTa | No | 25 | Carvedilol | Amiodarone | RBBB |
CAD = coronary artery disease; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; PVC = premature ventricular complex; RBBB = right bundle branch block; VT = ventricular tachycardia.
a
Incessant VT was defined as >3 episodes of sustained VT within a 24‐hour period and refractory to antiarrhythmic drugs.